Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021)

References

• Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015 Jul 2;1:15016. doi:10.1038/nrdp.2015.16. PMID: 27188665; PMCID: PMC5381807.
   PubMed Web of Science ®Google Scholar
• Dooling K, Marin M, Gershon AA. Clinical manifestations of Varicella: disease is largely forgotten, but it’s not gone. J Infect Dis. 2022 Oct 21;226(Suppl 4):S380–8. doi:10.1093/infdis/jiac390. PMID: 36265857; PMCID: PMC10205892.
   PubMed Web of Science ®Google Scholar
• Harbecke R, Jensen NJ, Depledge DP, Johnson GR, Ashbaugh ME, Schmid DS, Breuer J, Levin MJ, Oxman MN. Recurrent herpes zoster in the shingles prevention study: are second episodes caused by the same varicella-zoster virus strain? Vaccine. 2020 Jan 10;38(2):150–7. doi:10.1016/j.vaccine.2019.10.038.
   PubMed Web of Science ®Google Scholar
• Esteban-Vasallo MD, Domínguez-Berjón MF, Gil de Miguel Á, Astray-Mochales J, Blanco-Ancos LM, Gil-Prieto R. Characteristics of herpes zoster-associated hospitalizations in Madrid (SPAIN) before vaccine availability. J Infect. 2016 Jan;72(1):70–9. doi:10.1016/j.jinf.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Aldaz P, Díaz JA, Loayssa JR, Dronda MJ, Osacáriz M, Castilla J. Incidencia de herpes zóster en pacientes diabéticos. Anales Sis San Navarra [Internet]. Abr [citado 2023 Mayo 15]. 2013;36(1):57–62. doi:10.4321/S1137-66272013000100006.
   PubMedGoogle Scholar
• Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014 May 13;348:g2911. doi:10.1136/bmj.g2911.
   PubMed Web of Science ®Google Scholar
• Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017 Dec;92(12):1806–21. doi:10.1016/j.mayocp.2017.10.009.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency.Shingles (herpes zoster): the green book, chapter 28a. Published 12 July 2013. Last updated 23 August 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1012943/Green_book_of_immunisation_28a_Shingles.pdf.
   Google Scholar
• Amicizia D, Domnich A, Arata L, Zoli D, Zotti CM, Cacello E, Gualano MR, Gasparini R, Panatto D. The role of age-sex interaction in the development of post-herpetic neuralgia. Hum Vaccin Immunother. 2017 Feb;13(2):376–8. doi:10.1080/21645515.2017.1264799.
   PubMed Web of Science ®Google Scholar
• Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Resultados de la vigilancia Epidemiológica de las enfermedades transmisibles. Informe anual. Años 2017-2018. Madrid, 2020. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/INFORMES%20RENAVE/RENAVE_Informe_anual__2017-2018.pdf.
   Google Scholar
• Masa-Calles J, López-Perea N, Vila Cordero B, Carmona R. Vigilancia y epidemiología del herpes zóster en España [Surveillance and epidemiology of Herpes Zoster in Spain.]. Rev Esp Salud Publica. 2021 Jun 25; 95:e202106088. Spanish
   PubMed Web of Science ®Google Scholar
• van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021 Jun 3;17(6):1714–32. doi:10.1080/21645515.2020.1847582.
   PubMed Web of Science ®Google Scholar
• Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013 Apr 10;13(1):170. doi:10.1186/1471-2334-13-170.
   PubMedGoogle Scholar
• Arruti M, Piñeiro LD, Salicio Y, Cilla G, Goenaga MA, López de Munain A. Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007-2014). J Neurovirol. 2017 Jun;23(3):451–9. doi:10.1007/s13365-017-0519-y.
   PubMed Web of Science ®Google Scholar
• Grupo de trabajo de vacunación frente a herpes zóster de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, marzo 2021. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf.
   Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013 Sep 3; 81(10):928–30. doi:10.1212/WNL.0b013e3182a3516e.
   PubMed Web of Science ®Google Scholar
• Corcuera-Munguia M, Gil-Prieto R, Garcia-Carretero R, Gil-de-Miguel A. Hospitalization burden related to herpes zoster infection in Spain (2016-2019). Infect Dis Ther. 2023 Jan;12(1):143–56. doi:10.1007/s40121-022-00717-6.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44(Suppl 1):S1–26. doi:10.1086/510206.
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022 Apr 28;74(8):1459–67. doi:10.1093/cid/ciab629.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep 15;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Marra Y, Lalji F. Prevention of herpes zoster: a focus on the effectiveness and safety of herpes zoster vaccines. Viruses. 2022 Nov 29;14(12):2667. doi:10.3390/v14122667.
   PubMed Web of Science ®Google Scholar
• Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y, Servotte N, Shi M, Widenmaier R, Aris E. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022 Mar 9;9(5):ofac118. doi:10.1093/ofid/ofac118.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103–8. doi: 10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Barranco Quintana JL, García Cenoz M, Moza Moríñigo H, Onieva García MÁ, Rodríguez García J, Román Ortiz C (2022). Consenso de la SEMPSPGS sobre la vacunación frente a Herpes Zóster. Rev Esp Med Prev Salud Pública, 21–77. https://pesquisa.bvsalud.org/portal/resource/pt/ibc-212833
   Google Scholar
• Centro Nacional de Epidemiología, CIBERESP. Instituto de Salud Carlos III. Informe epidemiológico sobre la situación del Herpes Zóster en España, 1998-2018. Madrid, agosto 2020. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/archivos%20A-Z/HERPES%20ZOSTER/Informe_HZ_Espa%C3%B1a_1998-2018.pdf.
   Google Scholar
• Fillat ÁC, Ramón González-Juanatey J. COVID-19. Las consecuencias sociales, sanitarias y cardiovasculares. Revista Española de Cardiología Suplementos. 2020;20:1. doi:10.1016/S1131-3587(20)30027-3.
   Google Scholar
• Risco Risco C, Herrador Z, Lopez-Perea N, Martínez-Urbistondo D, Villar Carrero RS D, Masa-Calles J. Epidemiology of herpes zoster in the pre-vaccination era: establishing the baseline for vaccination programme’s impact in Spain. Euro Surveill. 2023 Feb;28(8):2200390. doi:10.2807/1560-7917.ES.2023.28.8.2200390.
   PubMedGoogle Scholar
• Maia CMF, Marques NP, de Lucena EHG, de Rezende LF, Martelli DRB, Martelli-Júnior H. Increased number of herpes zoster cases in Brazil related to the COVID-19 pandemic. Int J Infect Dis. 2021 Mar;104:732–3. doi:10.1016/j.ijid.2021.02.033.
   PubMed Web of Science ®Google Scholar
• Pourazizi M, Dehghani S, Abtahi-Naeini B. Herpes zoster oftálmico y COVID-19: ¿Complicación post-COVID-19 o coincidencia? [Herpes Zoster Ophthalmicus and COVID-19: A Post-COVID-19 Complication or a Coincidence? Actas Dermosifiliogr. 2022 Dec; 113:S16–S17. Spanish.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Parikh R, Bhavsar AB, Cisneros E, McCormick N, Lecrenier N. Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb). 2021 Aug;11(4):1119–26. doi:10.1007/s13555-021-00549-1.
   PubMed Web of Science ®Google Scholar
• Almutairi N, Almutairi AN, Almazyad M, Alwazzan S. Herpes zoster in the era of COVID 19: a prospective observational study to probe the association of herpes zoster with COVID-19 infection and vaccination. Dermatol Ther. 2022 Jul;35(7):e15521. doi:10.1111/dth.15521.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Lasagna A, Cassaniti I, Ferrari A, Bergami F, Silvestris N, Sapuppo E, Di Maio M, Cinieri S, Baldanti F. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open. 2022 Aug;7(4):100548. doi:10.1016/j.esmoop.2022.100548. Epub 2022 Jul 16. PMID: 35853350; PMCID: PMC9434335.
   PubMedGoogle Scholar
• Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc S, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi:10.1080/21645515.2023.2167907. Epub 2023 Mar 7. PMID: 36880669; PMCID: PMC10038038.
   PubMed Web of Science ®Google Scholar
• Kiderlen TR, Trostdorf K, Delmastro N, Salomon A, de Wit M, Reinwald M. Herpes zoster vaccination rates in hematological and oncological patients-stock taking 2 years after market approval. Healthcare (Basel). 2022 Aug 12;10(8):1524. doi:10.3390/healthcare10081524. PMID: 36011181; PMCID: PMC9408327.
   PubMedGoogle Scholar
• Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, Jones M, Kitchener E, Fox M, Johansson M, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021 Mar 16;11(3):e045343. doi:10.1136/bmjopen-2020-045343.
   PubMed Web of Science ®Google Scholar
• Cura-González I D, Polentinos-Castro E, Fontán-Vela M, López-Rodríguez JA, Martín-Fernández J. ¿qué hemos dejado de atender por la COVID-19? Diagnósticos perdidos y seguimientos demorados. Informe SESPAS 2022 [what have we missed because of COVID-19? Missed diagnoses and delayed follow-ups. SESPAS report 2022. Gac Sanit. 2022;36(Suppl 1):S36–S43. Spanish. doi:10.1016/j.gaceta.2022.03.003.
   PubMedGoogle Scholar
• Achilleos S, Quattrocchi A, Gabel J, Heraclides A, Kolokotroni O, Constantinou C, Pagola Ugarte M, Nicolaou N, Rodriguez-Llanes JM, Bennett CM, et al. Excess all-cause mortality and COVID-19-related mortality: a temporal analysis in 22 countries, from January until August 2020. Int J Epidemiol. 2022 Feb 18;51(1):35–53. doi:10.1093/ije/dyab123.
   PubMed Web of Science ®Google Scholar
• Ortiz-Cardenas M, Solis-Taquire L, Osada-Liy J. Discontinuidad en el tratamiento de los pacientes con enfermedades crónicas durante la pandemia por la COVID-19. Rev Cubana Med [Internet]. 2020 [citado 15 May 2023];60(3).
   Google Scholar
• Huenchuan S, La pandemia por COVID-19 y su relación con las enfermedades no transmisibles y la protección social en salud (LC/MEX/TS.2021/18). Ciudad de México, Comisión Económica para América Latina y el Caribe (CEPAL). 2021.
   Google Scholar
• Gil A, Gil R, Alvaro A, San Martín M, González A. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis. 2009 May 7;9:55. doi:10.1186/1471-2334-9-55.
   PubMed Web of Science ®Google Scholar
• Bongers LD, Navarini A, Berger CT, Mueller SM. Complications and cost estimations in herpes zoster - a retrospective analysis at a Swiss tertiary dermatology clinic. Swiss Med Wkly. 2021 Dec 28;151:w30081. doi:10.4414/smw.2021.w30081. PMID: 34964592.
   PubMed Web of Science ®Google Scholar
• Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A, Zoster-049 Study Group. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim Efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi:10.1093/ofid/ofac485.
   PubMed Web of Science ®Google Scholar
• Giannelos N, Ng C, Curran D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review. Hum Vaccin Immunother. 2023 Dec 31;19(1):2168952. doi:10.1080/21645515.2023.2168952. Epub 2023 Mar 14. PMID: 36916240; PMCID: PMC10054181.
   PubMed Web of Science ®Google Scholar